Ivert Torbjörn, Boano Gabriella, Vanky Farkas, Gadler Fredrik, Holmgren Anders, Jidéus Lena, Johansson Birgitta, Kennebäck Göran, Nozohoor Shahab, Scherstén Henrik, Sjögren Johan, Wickbom Anders, Friberg Örjan, Albåge Anders
Department of Cardiothoracic Surgery, Karolinska University Hospital and Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Thoracic and Vascular Surgery, Unit of Cardiovascular Medicine, Linköping University, Linköping, Sweden.
Interdiscip Cardiovasc Thorac Surg. 2025 Mar 29;40(4). doi: 10.1093/icvts/ivaf085.
This study evaluated the long-term risk of permanent pacemaker implantation following Cox-maze IV (CMIV) and concurrent mitral valve surgery.
A retrospective, nationwide, registry-based analysis was conducted on postoperative permanent pacemaker implantation in 397 patients with symptomatic mitral valve insufficiency and atrial fibrillation who underwent CMIV and mitral valve surgery in Sweden between 2009 and 2017. They were compared to a registry group of 346 patients with atrial fibrillation who underwent mitral valve surgery without surgical ablation during 2014-2017. The follow-up ended on 30 September 2022.
CMIV patients were on average 4 years younger and had lower surgical risk than registry patients. More CMIV patients underwent early (<30 days) pacemaker implantation (13.3% vs. 5.5%, P = 0.002). CMIV patients had a doubled adjusted risk of requiring a pacemaker compared to registry patients after 8 years [HR 1.96, 95% CI 1.27-3.04]. In the CMIV group, 22% (95% CI 18-26%) had a pacemaker by 5 years, increasing to 27% (95% CI 22-31%) by 8 years, compared to 13% (95% CI 10-17%) at both time intervals in the registry group. Atrioventricular block II/III accounted for >60% of early pacemaker indications in both groups, and sinus node dysfunction was the indication for late pacemaker implantation in 48% in the CMIV group.
Patients undergoing CMIV concomitant with mitral valve surgery have a higher rate of postoperative pacemaker implantation compared to patients with atrial fibrillation undergoing mitral valve surgery alone. Sinus node dysfunction was the main indication for late pacemaker among CMIV patients.
本研究评估了Cox迷宫IV手术(CMIV)联合二尖瓣手术后置入永久性起搏器的长期风险。
对2009年至2017年期间在瑞典接受CMIV和二尖瓣手术的397例有症状二尖瓣反流和心房颤动患者术后永久性起搏器植入情况进行了一项基于全国登记处的回顾性分析。将他们与2014年至2017年期间接受二尖瓣手术但未进行手术消融的346例心房颤动登记组患者进行比较。随访截至2022年9月30日。
CMIV组患者平均比登记组患者年轻4岁,手术风险更低。更多CMIV组患者在早期(<30天)植入起搏器(13.3%对5.5%,P = 0.002)。8年后,CMIV组患者需要起搏器的调整后风险是登记组患者的两倍[风险比1.96,95%置信区间1.27 - 3.04]。在CMIV组中,到5年时有22%(95%置信区间18 - 26%)植入了起搏器,到8年时增至27%(95%置信区间22 - 31%),而登记组在这两个时间点的比例均为13%(95%置信区间10 - 17%)。两组中,房室传导阻滞II/III型占早期起搏器植入指征的60%以上,CMIV组中48%的患者因窦房结功能障碍成为晚期起搏器植入指征。
与单纯接受二尖瓣手术的心房颤动患者相比,接受CMIV联合二尖瓣手术的患者术后起搏器植入率更高。窦房结功能障碍是CMIV组患者晚期起搏器植入的主要指征。